ArticleHaematologica2026

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Bradley Rockwell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.